Physician profile
Michael R Dash
NPI 1033164959
$454.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $90.36 · 2021: $77.28 · 2022: $37.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $82.26 | 2019-2020 | |
| Lilly USA, LLC | $54.72 | 2019-2020 | |
| Pfizer INC. | $49.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $33.17 | 2019 | |
| Novo Nordisk INC | $31.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.64 | 2019 | |
| Merck Sharp & Dohme LLC | $27.29 | 2020-2021 | |
| Allergan, INC. | $27.07 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $26.77 | 2019 | |
| Amarin Pharma, INC. | $24.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.48 | 2021 | |
| Amgen INC. | $14.00 | 2019 | |
| Abbvie INC. | $13.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.96 | 2019 | |
| Glaxosmithkline, LLC. | $11.85 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.